BioLargo (BLGO) & Its Competitors Financial Contrast

BioLargo (NASDAQ:BLGO) is one of 34 public companies in the “Chemicals & allied products” industry, but how does it weigh in compared to its competitors? We will compare BioLargo to similar businesses based on the strength of its analyst recommendations, valuation, dividends, profitability, institutional ownership, earnings and risk.

Insider and Institutional Ownership

0.0% of BioLargo shares are held by institutional investors. Comparatively, 68.4% of shares of all “Chemicals & allied products” companies are held by institutional investors. 20.3% of BioLargo shares are held by insiders. Comparatively, 10.1% of shares of all “Chemicals & allied products” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares BioLargo and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioLargo	$12.23 million	-$3.50 million	-8.06
BioLargo Competitors	$6.63 billion	$204.21 million	65.95

BioLargo’s competitors have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

BioLargo has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, BioLargo’s competitors have a beta of 1.78, indicating that their average share price is 78% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for BioLargo and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLargo	0	0	0	0	N/A
BioLargo Competitors	139	1282	1596	46	2.51

As a group, “Chemicals & allied products” companies have a potential upside of 6.99%. Given BioLargo’s competitors higher probable upside, analysts plainly believe BioLargo has less favorable growth aspects than its competitors.

Profitability

This table compares BioLargo and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLargo	-16.53%	-58.35%	-32.12%
BioLargo Competitors	-568.74%	5.73%	-0.15%

Summary

BioLargo competitors beat BioLargo on 8 of the 10 factors compared.

About BioLargo

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.